ArticleOncology letters2018
Relationship between the genetic expression of WTAP and bladder cancer and patient prognosis.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 39 citations in OpenAlex.
- RNA methylation in urological cancers: regulatory logic, biological functions, and clinical relevance.Frontiers in immunology · 2026Review
- Emerging implications of N6-methyladenosine in prostate cancer progression and treatment.Cell death discovery · 2025Review
- The diverse landscape of RNA modifications in cancer development and progression.Genes & genomics · 2025Review
- WTAP promotes proliferation of esophageal squamous cell carcinoma via mCancer science · 2024Article
- WTAP enhances the instability of SYTL1 mRNA caused by YTHDF2 in bladder cancer.Histology and histopathology · 2024Article
- The Role of Long Noncoding RNAs (lncRNAs) in Esophageal Cancer Therapy Resistance and Metastasis.Biomedicines · 2024Review
- PIGT promotes cell growth, glycolysis, and metastasis in bladder cancer by modulating GLUT1 glycosylation and membrane trafficking.Journal of translational medicine · 2024Article
- The role of RNA modification in urological cancers: mechanisms and clinical potential.Discover oncology · 2023Review
- Wilms tumor 1 associated protein promotes epithelial mesenchymal transition of gastric cancer cells by accelerating TGF-β and enhances chemoradiotherapy resistance.Journal of cancer research and clinical oncology · 2023Article
- The emerging roles and mechanism of N6-methyladenosine (mFrontiers in pharmacology · 2023Review
- WTAP regulates postnatal development of brown adipose tissue by stabilizing METTL3 in mice.Life metabolism · 2022Article
- The RNA mCell death & disease · 2022Review
- Role of WTAP in Cancer: From Mechanisms to the Therapeutic Potential.Biomolecules · 2022Review
- Processing body (P-body) and its mediators in cancer.Molecular and cellular biochemistry · 2022Review
- Upregulated WTAP expression appears to both promote breast cancer growth and inhibit lymph node metastasis.Scientific reports · 2022Article
- Comprehensive analysis about prognostic and immunological role of WTAP in pan-cancer.Frontiers in genetics · 2022Article
- Upregulated WTAP expression in colorectal cancer correlates with tumor site and differentiation.PloS one · 2022Article
- Clinical and molecular significance of the RNA mFrontiers in genetics · 2022Article
- m6A RNA methylation regulators were associated with the malignancy and prognosis of ovarian cancer.Bioengineered · 2021Article
- N6-Methyladenosine Regulators Are Involved in the Progression of and Have Clinical Impact on Breast Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between the gene expression of Wilms tumor 1-associated protein (WTAP) and bladder cancer was investigated to study the effect of its expression on patient prognosis. Sixty-two fresh specimens of bladder transitional cell cancer tissues were collected as the bladder cancer group, while 20 normal bladder mucosa specimens comprised the control group. Hematoxylin and eosin staining was conducted to detect the pathological differences between the groups and the immunohistochemistry was used to test the expression levels of WTAP in the tissues. Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the mRNA expression levels of WTAP. Moreover, western blot analysis was used to examine the WTAP expression levels. At the same time, Cox regression multi-factor survival analysis was conducted for the related factors to the prognoses of bladder cancer patients. The structures of cells in the bladder cancer group were destroyed as was evident by the shrunken cell nuclei, while the tissues in the control group were intact. WTAP expression in the bladder cancer group was significantly increased compared with that in the control group. A small number of mRNAs and proteins were higher in the bladder cancer group than that in the control group. The differences in WTAP expression between the bladder cancer and control groups were statistically significant (P<0.05). There were obvious differences in the postoperative recurrence risk between the patients with a negative WTAP protein expression and those with a positive one (P<0.05). In conclusion, WTAP may play an important role in the occurrence and development of bladder cancer and can be considered as a potential target for bladder cancer treatment, providing a new basis for clinical diagnoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.